Fortress生物科技 FBIO 深 滬
已收盤 12-12 16:00:00 美东时间
2.93
-0.010
-0.34%
華盛通- 最 高3.00
- 今 開2.95
- 成交量 18.65万股
- 最 低 2.90
- 昨 收 2.94
- 總市值 8718.16万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 1.325
- 委 比 -97.67%
- 總股本 2975.48万
- 歷史最高 190.50
- 量 比 0.81
- 振 幅 3.40%
- 歷史最低 1.325
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Journey Medical Corporation announced positive results from a Phase 1 clinical trial of Emrosi, a low-dose oral minocycline for rosacea. The trial met all primary objectives, showing no significant impact on skin, GI tract, or vaginal microbiota, and no safety issues over 16 weeks. Emrosi is FDA-approved for treating inflammatory lesions in adults. The study, published in the Journal of Drugs in Dermatology, supports its long-term use and safety ...
12-10 13:30
Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.42) by 126.19 percent. This is a 114.47 percent increase over losses of $(0.76) per share
11-14 21:43
Fortress Biotech Q3 Earnings Preview
Fortress Biotech (FBIO) is scheduled to announce Q3 earnings results on Wednesday, November 12th, after market close. The consensus EPS Estimate is -$0.63 and the consensus Revenue Estimate is $21.02M...
11-12 06:35
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Avenue Therapeutics and its subsidiary Baergic Bio have agreed to be acquired by Axsome Therapeutics for up to $82 million in potential milestones and royalties. The acquisition includes global rights to BAER-101, a novel epilepsy treatment, now to be known as AXS-17. Avenue expects to receive approximately 74% of future payments and royalties under the agreement. Baergic shareholders are eligible for up to $79 million in sales-based milestones a...
11-06 12:00
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Journey Medical Corporation will release its third quarter 2025 financial results after U.S. markets close on November 12, 2025. A conference call and audio webcast will be held on the same day at 4:30 p.m. ET. Interested parties can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join, or access the webcast via the company’s website. A replay will be available for 30 days. The company focuses on selling and marketing FDA-appr...
11-05 13:30
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Urica Therapeutics subsidiary Crystalys Therapeutics initiated Phase 3 trials (RUBY and TOPAZ) for dotinurad, a once daily URAT1 inhibitor for gout. The trials will assess safety and efficacy in 500 and 250 patients, respectively, with gout. Fortress Biotech's Lindsay Rosenwald highlighted the potential for advancing dotinurad in the U.S. and Europe. Urica holds a minority stake in Crystalys and is entitled to a 3% royalty on dotinurad sales. The...
10-21 12:30
Fortress Biotech plunges as FDA rejects rare disease drug
Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its Indi...
10-01 20:59
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
Shares of Ryvyl Inc (NASDAQ:RVYL) rose sharply in pre-market trading after the ...
10-01 17:45
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Urica Therapeutics has sold dotinurad to Crystalys Therapeutics for equity and a 3% royalty. Crystalys secured $205 million in Series A financing to advance global Phase 3 trials for gout. Dotinurad, a next-gen URAT1 inhibitor, has shown strong efficacy and safety, approved in Japan, China, Philippines, and Thailand. This transaction enhances Fortress Biotech's asset value and supports dotinurad's potential approval in the U.S. and Europe.
10-01 12:05
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for CUTX-101's NDA to treat Menkes disease. Sentynl Therapeutics, now responsible for CUTX-101's development, plans to address FDA concerns and resubmit the application. The CRL cited manufacturing deficiencies but no efficacy or safety issues. CUTX-101 holds significant promise for improving survival in Menkes disease, wi...
10-01 12:00
